Alicia Granados | Head, Global Rare Diseases Medical Scientific Advocacy
Sanofi

Alicia Granados is a highly accomplished leader in the field of rare diseases, currently serving as the Head of Global Rare Diseases Medical Scientific Advocacy at Sanofi, where previously she headed its global HTA strategy .With almost 15 years of experience in the pharmaceutical industry, Alicia has dedicated her career to advancing the development and accessibility of orphan drugs for patients with rare diseases.

Alicia is known for her strategic vision and innovative approach to addressing the unique challenges faced by the orphan drug industry. She has a proven track record of building successful partnerships with key stakeholders, including patient advocacy groups, regulatory agencies, and healthcare providers, to drive forward initiatives that improve patient outcomes and access to life-changing therapies. She is MD,  certified specialist in respiratory medicine and PhD in Public health from the University of Barcelona where she was associate professor of Medicine with focus on Health Technology Assessment science, evidence based medicine  and evidence based health care. She was the first President of the International Society for Technology Assessment (HTAi) and founder member of INAHTA and currently is  co-Chair the HTAi Rare Diseases Interest Group. She has advised several UN agencies on Evidence Based Health Care, was Acting Regional Advisor of WHO European Office and   has published more than 70 scientific and policy papers, related to respiratory medicine, HTA and Rare Disorders. Alicia Granados, MD, PhD PH | LinkedIn At the World Orphan Drug Congress 2025, Alicia will share her expertise on strategy, scientific advocacy, and partnering in the orphan drug industry, offering valuable insights and practical guidance for industry professionals looking to make a positive impact in the lives of patients with rare diseases.